Zhiyong He - Department of Medical Oncology, Fujian Provincial Cancer Hospital

基本信息

浏览量：3

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 39 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Socazolimab or Placebo Combined with Carboplatin and Etoposide in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Zhiwei Chen,Jianhua Chen,Dingzhi Huang,Wei Zhang,Lin Wu,Tienan Yi,Qiming Wang,Liang Han,Liping Tan,Yinyin Li,Zhihong Zhang, Na Li,Jie li,Tongmei Zhang,Ying Hu, Hongmei Sun,Youhua Wu,Zhiyong He,Runxiang Yang, Peng Cheng,Xingya Li,Jianhua Shi,Guohua Yu,Daiyuan Ma,Benjamin Xiaoyi Li,Xiangrong Dai, Michael Wong, Yujie Li, Xiaohui Yu,Shun Lu

Signal Transduction and Targeted Therapyno. 1 (2025): 1-8

引用0浏览0WOSNATURE引用

Rezivertinib Versus Gefitinib As First-Line Therapy for Patients with EGFR-mutated Locally Advanced or Metastatic Non-Small-cell Lung Cancer (REZOR): a Multicentre, Double-Blind, Randomised, Phase 3 Study

Yuankai Shi,Yanzhen Guo,Xingya Li,Lin Wu,Zhaohong Chen,Sheng Yang,Minghong Bi,Yanqiu Zhao,Wenxiu Yao,Huiqing Yu,Ke Wang,Wenhua Zhao,Meili Sun,Liangming Zhang,Zhiyong He, Yingcheng Lin,Jianhua Shi,Bo Zhu, Lijun Wang,Yueyin Pan

The Lancet Respiratory Medicine (2025)

引用0浏览0WOS引用

Efficacy and Safety of Metronomic Oral Vinorelbine and Its Combination Therapy As Second- and Later-Line Regimens for Advanced Non-Small-cell Lung Cancer: a Retrospective Analysis

ShiJie Chen,ZhiYong He,MeiFang Li,LiHong Weng,JingHui Lin

Clinical and Translational Oncologypp.1-9, (2024)

引用0浏览0WOS引用

First-line Penpulimab Combined with Paclitaxel and Carboplatin for Metastatic Squamous Non-Small-cell Lung Cancer in China (AK105-302): a Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial

LANCET RESPIRATORY MEDICINEno. 5 (2024): 355-365

引用9浏览0WOS引用

Rezivertinib Versus Gefitinib As First-line Therapy for EGFR-mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-blinded, Randomized Phase 3 Study

crossref（2024）

引用0浏览0引用

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONno. 7 (2024): 561-570

引用0浏览0WOS引用

Tifcemalimab Combined with Toripalimab and Chemotherapy As 1st Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Phase Ib/II, Open-Label Study

Yongfeng Yu,Yan Yu,Yan Zhang,Wei Zhang,Dongqing Lv,Yuan Chen,Dingzhi Huang,Mingjun Zhang,Yongsheng Li,Dairong Li,Junzhen Gao,Lin Wu,Zhiyong He,Jianhua Shi,Mingfang Zhao,Anwen Liu,Chunyue Wang, Hui Zhu,Shun Lu

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Ivonescimab Combined with Chemotherapy in Patients with EGFR-mutant Non-Squamous Non-Small Cell Lung Cancer Who Progressed on EGFR Tyrosine-Kinase Inhibitor Treatment (Harmoni-A): A Randomized, Double-Blind, Multi-Center, Phase 3 Trial

Li Zhang,Wenfeng Fang,Yuanyuan Zhao,Yongzhong Luo,Runxiang Yang,Yan Huang,Zhiyong He,Hui Zhao,Mingjun Li,Kai Li,Qibin Song,Xiaobo Du,Yulan Sun,Wei Li,Fei Xu,Zhiyu Wang, Kunning Yang,Yun Fan,Wenting Li,Yu Xia

Journal of Clinical Oncologyno. 16_suppl (2024): 8508-8508

引用0浏览0引用

Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study

JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 11 (2024)

引用0浏览0WOS引用

Abstract CT076: Randomized, Global, Phase 3 Study of Tislelizumab Plus Chemotherapy Versus Chemotherapy As First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-306): China Subgroup Analysis

Yongqian Shu,Yueyin Pan,Ping Lu, Yi Jiang,Jingdong Zhang,Xiaohong Wu,Yuanhu Yao,Lin Shen,Yi Ba,Zhiyong He,Yuxian Bai,Jianhua Chen,Guohua Yu, Yanyan Peng, Hongqian Wu,Lei Wang,Liyun Li,Jianming Xu

CANCER RESEARCHno. 8 (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn